Shattuck Labs to Present at TIGIT Therapies Digital Summit 2020
Presentation Title: Using LIGHT to Hotwire TIGIT Blockade
The presentation will be available for download on the Events & Presentations section of the Company’s website and also will be available to registered participants of TIGIT Therapies Digital Summit 2020.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint platform, ARC®, simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with
Director of Finance
Stern Investor Relations, Inc.